Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Ovarian Research
Published in: Journal of Ovarian Research 1/2016

Open Access 01-12-2016 | Research

The association between CDH1 promoter methylation and patients with ovarian cancer: a systematic meta-analysis

Authors: Qiang Wang, Bing Wang, Yun-mei Zhang, Wei Wang

Published in: Journal of Ovarian Research | Issue 1/2016

Login to get access

Abstract

Background

The down-regulation of E-cadherin gene (CDH1) expression has been regarded as an important event in cancer invasion and metastasis. However, the association between CDH1 promoter methylation and ovarian cancer remains unclear. A meta-analysis was conducted to evaluate the potential role of CDH1 promoter methylation in ovarian cancer.

Methods

Relevant articles were identified by searches of PubMed, EMBASE, Cochrane Library, CNKI and Wanfang databases. The pooled odds ratio (OR) and corresponding 95 % confidence interval (CI) were calculated to assess the strength of association.

Results

Nine studies were performed using the fixed-effects model in this study, including 485 cancer tissues and 255 nonmalignant tissues. The findings showed that CDH1 promoter methylation had an increased risk of ovarian cancer in cancer tissues (OR = 8.71, P < 0.001) in comparison with nonmalignant tissues. Subgroup analysis of the ethnicity showed that the OR value of CDH1 methylation in Asian population subgroup (OR = 13.20, P < 0.001) was higher than that in Caucasian population subgroup (OR = 3.84, P = 0.005). No significant association was found between ovarian cancer and low malignant potential (LMP) tumor (P = 0.096) among 2 studies, and between CDH1 promoter methylation and tumor stage and tumor histology (all P > 0.05). There was not any evidence of publication bias by Egger’s test (all P > 0.05).

Conclusions

CDH1 promoter methylation can be a potential biomarker in ovarian cancer risk prediction, especially Asians can be more susceptible to CDH1 methylation. However, more studies are still done in the future.
Literature
1.
2.
Kaja S et al. Detection of novel biomarkers for ovarian cancer with an optical nanotechnology detection system enabling label-free diagnostics. J Biomed Opt. 2012;17(8):0814121–8.CrossRef
3.
4.
Network CGAR. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–15.CrossRef
5.
Khan SA, Reddy D, Gupta S. Global histone post-translational modifications and cancer: Biomarkers for diagnosis, prognosis and treatment? World J Biol Chem. 2015;6(4):333–45.CrossRefPubMedPubMedCentral
6.
Pouliot M-C et al. The role of methylation in breast cancer susceptibility and treatment. Anticancer Res. 2015;35(9):4569–74.PubMed
7.
8.
9.
Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349(21):2042–54.CrossRefPubMed
10.
Esteller M, Herman JG. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol. 2002;196(1):1–7.CrossRefPubMed
11.
12.
Berx G et al. E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J. 1995;14(24):6107–15.PubMedPubMedCentral
13.
Oka H et al. Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res. 1993;53(7):1696–701.PubMed
14.
Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science. 1991;251(5000):1451–5.CrossRefPubMed
15.
Tsanou E et al. The E-cadherin adhesion molecule and colorectal cancer. A global literature approach. Anticancer Res. 2008;28(6A):3815–26.PubMed
16.
Coory MD. Comment on: Heterogeneity in meta-analysis should be expected and appropriately quantified. Int J Epidemiol. 2010;39(3):932.CrossRefPubMed
17.
18.
DerSimonian R. Meta-analysis in the design and monitoring of clinical trials. Stat Med. 1996;15(12):1237–48.CrossRefPubMed
19.
Peters JL et al. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295(6):676–80.CrossRefPubMed
20.
Bhagat R et al. Altered expression of β-catenin, E-cadherin, and E-cadherin promoter methylation in epithelial ovarian carcinoma. Tumor Biol. 2013;34(4):2459–68.CrossRef
21.
Makarla PB et al. Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res. 2005;11(15):5365–9.CrossRefPubMed
22.
Moselhy SS et al. Hypermethylation of P15, P16, and E-cadherin genes in ovarian cancer. Toxicol Ind Health. 2015;31(10):924–30.CrossRefPubMed
23.
Shen WJ et al. Promoter hypermethylation of CDH1 gene in epithelial ovarian carcinoma. Chin J Pract Gynecol Obstet. 2007;23(07):520–2.
24.
Sun B, Zhang X. Value of abnormal methylation of CDH1 gene and the detection of serum HE4 in the identification of ovarian cancer and ovarian endometriosis cyst. Hainan Med J. 2015;26(20):3023–5.
25.
Wu X et al. Clinical importance and therapeutic implication of E-cadherin gene methylation in human ovarian cancer. Med Oncol. 2014;31(8):1–8.
26.
Yuecheng Y, Hongmei L, Xiaoyan X. Clinical evaluation of E-cadherin expression and its regulation mechanism in epithelial ovarian cancer. Clin Exp Metastasis. 2006;23(1):65–74.CrossRefPubMed
27.
Bodmer W. 1998 Runme Shaw Memorial Lecture: somatic evolution of cancer. Ann Acad Med Singapore. 1999;28(3):323–9.PubMed
28.
Corson TW, Gallie BL. One hit, two hits, three hits, more? Genomic changes in the development of retinoblastoma. Genes Chromosomes Cancer. 2007;46(7):617–34.CrossRefPubMed
29.
Franco R et al. Oxidative stress, DNA methylation and carcinogenesis. Cancer Lett. 2008;266(1):6–11.CrossRefPubMed
30.
Yoshiura K et al. Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci. 1995;92(16):7416–9.CrossRefPubMedPubMedCentral
31.
Tamura G et al. E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas. J Natl Cancer Inst. 2000;92(7):569–73.CrossRefPubMed
32.
Fearon ER. BRCA1 and E-Cadherin promoter hypermethylation and gene inactivation in cancer—association or mechanism? J Natl Cancer Inst. 2000;92(7):515–7.CrossRefPubMed
33.
34.
Montavon C et al. Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer. Gynecol Oncol. 2012;124(3):582–8.CrossRefPubMed
35.
Rathi A et al. Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin Cancer Res. 2002;8(11):3324–31.PubMed
36.
Karahalios A et al. A review of the reporting and handling of missing data in cohort studies with repeated assessment of exposure measures. BMC Med Res Methodol. 2012;12(1):96.CrossRefPubMedPubMedCentral
Metadata
Title
The association between CDH1 promoter methylation and patients with ovarian cancer: a systematic meta-analysis
Authors
Qiang Wang
Bing Wang
Yun-mei Zhang
Wei Wang
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Journal of Ovarian Research / Issue 1/2016
Electronic ISSN: 1757-2215
DOI
https://doi.org/10.1186/s13048-016-0231-1

Other articles of this Issue 1/2016

Journal of Ovarian Research 1/2016 Go to the issue

Research

Developmental programming: rescuing disruptions in preovulatory follicle growth and steroidogenesis from prenatal testosterone disruption

Review

Used protocols for isolation and propagation of ovarian stem cells, different cells with different traits

Research

Prophylactic salpingo-oophorectomy in BRCA1 mutation carriers and postoperative incidence of peritoneal and breast cancers

Research

NPR2 is involved in FSH-mediated mouse oocyte meiotic resumption

Research

Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer

Research

Comparison of quartz vials with polypropylene vials for rapid cryopreservation of human ovarian tissue